Literature DB >> 2467502

Histochemical and X-ray microanalytical localization of aluminum in amyotrophic lateral sclerosis and parkinsonism-dementia of Guam.

P Piccardo1, R Yanagihara, R M Garruto, C J Gibbs, D C Gajdusek.   

Abstract

Histochemical staining for aluminum, using Solochrome azurine or Morin, provided a rapid, simple and reliable means of identifying areas and structures of the brain of interest for closer scrutiny by X-ray microanalysis in patients with amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neuronal perikarya, dendritic processes, and the walls of some cerebral vessels were aluminum positive by Solochrome azurine staining. In some cases, the deposition of aluminum was rather diffuse, particularly in the white matter. Fluorescent localization of aluminum using Morin was equally sensitive and specific, but provided less morphological detail than Solochrome azurine. Confirmation of histochemical detection of aluminum was achieved by examining adjacent tissue sections using wavelength-dispersive spectrometry coupled to a computer-controlled electron beam X-ray microprobe. Although the minimum detectable limits for aluminum by these histochemical procedures are unknown, the lower detection limit of our X-ray microanalytical technique is 10-100 ppm dry weight. Solochrome and Morin staining, as verified by X-ray microanalysis, afford a useful and reliable means of surveying multiple anatomical regions for aluminum deposition in naturally occurring and experimentally induced neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2467502     DOI: 10.1007/bf00688235

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  13 in total

1.  EXPERIMENTAL PRODUCTION OF NEUROFIBRILLARY DEGENERATION. I. LIGHT MICROSCOPIC OBSERVATIONS.

Authors:  I KLATZO; H WISNIEWSKI; E STREICHER
Journal:  J Neuropathol Exp Neurol       Date:  1965-04       Impact factor: 3.685

2.  Intraneuronal deposition of calcium and aluminium in amyotropic lateral sclerosis of Guam.

Authors:  R M Garruto; C Swyt; C E Fiori; R Yanagihara; D C Gajdusek
Journal:  Lancet       Date:  1985-12-14       Impact factor: 79.321

3.  Aluminum as a factor in the bone disease of long-term parenteral nutrition.

Authors:  G L Klein; S M Ott; A C Alfrey; D J Sherrard; T K Hazlet; N L Miller; N A Maloney; W E Berquist; M E Ament; J W Coburn
Journal:  Trans Assoc Am Physicians       Date:  1982

4.  Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons.

Authors:  D P Perl; A R Brody
Journal:  Science       Date:  1980-04-18       Impact factor: 47.728

5.  Aluminosilicates and senile plaque formation in Alzheimer's disease.

Authors:  J M Candy; A E Oakley; J Klinowski; T A Carpenter; R H Perry; J R Atack; E K Perry; G Blessed; A Fairbairn; J A Edwardson
Journal:  Lancet       Date:  1986-02-15       Impact factor: 79.321

6.  Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam.

Authors:  D P Perl; D C Gajdusek; R M Garruto; R T Yanagihara; C J Gibbs
Journal:  Science       Date:  1982-09-10       Impact factor: 47.728

7.  Histochemical localization of aluminum in the rabbit CNS.

Authors:  G Y Wen; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

8.  Imaging of calcium and aluminum in neurofibrillary tangle-bearing neurons in parkinsonism-dementia of Guam.

Authors:  R M Garruto; R Fukatsu; R Yanagihara; D C Gajdusek; G Hook; C E Fiori
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

9.  Evidence of aluminum loading in infants receiving intravenous therapy.

Authors:  A B Sedman; G L Klein; R J Merritt; N L Miller; K O Weber; W L Gill; H Anand; A C Alfrey
Journal:  N Engl J Med       Date:  1985-05-23       Impact factor: 91.245

10.  Aluminum loading during total parenteral nutrition.

Authors:  G L Klein; A C Alfrey; N L Miller; D J Sherrard; T K Hazlet; M E Ament; J W Coburn
Journal:  Am J Clin Nutr       Date:  1982-06       Impact factor: 7.045

View more
  7 in total

Review 1.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

Review 2.  A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans.

Authors:  N Chernoff; D J Hill; D L Diggs; B D Faison; B M Francis; J R Lang; M M Larue; T-T Le; K A Loftin; J N Lugo; J E Schmid; W M Winnik
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2017-06-09       Impact factor: 6.393

3.  Low-calcium, high-aluminum diet-induced motor neuron pathology in cynomolgus monkeys.

Authors:  R M Garruto; S K Shankar; R Yanagihara; A M Salazar; H L Amyx; D C Gajdusek
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

4.  Interaction of aluminum with PHFtau in Alzheimer's disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method.

Authors:  H Murayama; R W Shin; J Higuchi; S Shibuya; T Muramoto; T Kitamoto
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

5.  Aluminium-induced tangles in cultured rat neurones. Enhanced effect of aluminium by addition of maltol.

Authors:  D Langui; A Probst; B Anderton; J P Brion; J Ulrich
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

6.  Lack of topographical relationship between sites of aluminum deposition and senile plaques in the Alzheimer's disease brain.

Authors:  P Kasa; P Szerdahelyi; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

7.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.